IsoTherapeutics, in collaboration with the Gabriel
Institute and Valco Instruments Company, Inc. has developed a novel
method to treat solid inoperable tumors. Traditional
brachytherapy uses encapsulated gamma emitters and irradiation of
non-target tissue is a big issue. Beta emitters, which
would have a much smaller field of irradiation, have not been
used in this manner because the capsules would effectively shield
the beta particles. Use of beta emitters without
encapsulation would normally result in the migration of isotope
and thus radiation dose to non-target tissues. Liquid
Brachytherapy involves a simple and effective chemical approach
to immobilizing metallic radioisotopes. This technology is
protected by PCT patent application WO 2009/045230.
This technology is available for license.